In the context of the Women’s Interagency HIV Study (WIHS) research, the identification of IGF2BP2 as a significant determinant in antiretroviral therapy has revealed its capacity to modulate the genetic impacts of established risk variants linked to type 2 diabetes (84). The gene discussed is IGF2BP2; the disease is type 2 diabetes mellitus.